SETPOINTSetPoint Medical, then a clinical-stage medical device company, was advancing a novel neuroimmune modulation therapy for rheumatoid arthritis and other inflammatory conditions while navigating the capital-intensive demands of clinical development and regulatory approval.
To support this phase, SetPoint initially secured a $35 million credit facility from Runway Growth Capital, providing flexible, non-dilutive financing to advance clinical trials, regulatory efforts, and early commercialization while preserving ownership and control.
The financing enabled SetPoint to progress its RESET-RA clinical trial, a critical milestone that positioned the company for FDA approval and market entry in July 2025. As the program continued to advance, Runway re-iterated its’ support for SetPoint, increasing its’ commitment to $65mn, allowing SetPoint to benefit from disciplined financial structuring and growth capital tailored to the timing and demands of clinical development, helping the company maintain long-term financial stability. The facility also supported early commercialization initiatives, including market education, clinical validation, and infrastructure development.
Today, the SetPoint Medical team continues to advance a new class of neuroimmune modulation therapies designed to offer a differentiated alternative to traditional drug-based treatments. Runway’s flexible growth financing supported SetPoint’s clinical and commercial objectives while providing a strong foundation for long-term execution.
